Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

Autor:	Ki Hyeong Lee1 kihlee@chungbuk.ac.kr, Byoung Chul Cho2, Myung-Ju Ahn3, Yun-Gyoo Lee4, Youngjoo Lee5, Jong-Seok Lee6, Joo-Hang Kim7, Young Joo Min8, Gyeong-Won Lee9, Sung Sook Lee10, Kyung-Hee Lee11, Yoon Ho Ko12, Byoung Yong Shim13, Sang-We Kim14, Sang Won Shin15, Jin-Hyuk Choi16, Dong-Wan Kim17, Eun Kyung Cho18, Keon Uk Park19, Jin-Soo Kim20
Zdroj:	Cancer Research & Treatment. Jan2024, Vol. 56 Issue 1, p48-60. 13p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu